文献速递类风湿关节炎

甲氨蝶呤治疗类风湿关节炎的时序免疫动态

Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy.
PubMed 文献 · Ann Rheum Dis · 2026-06-11

本研究对6例新诊断类风湿关节炎患者启动甲氨蝶呤治疗前后进行单细胞多组学纵向分析,发现治疗3周内即出现快速免疫重塑,早于临床改善。滤泡辅助性T细胞和浆母细胞在临床应答者中选择性下降,在无应答者中基本不变,并在22例独立队列及外部数据集中验证。

要点

  • 甲氨蝶呤诱导的免疫重塑最早在治疗3周时可检测到,且早于临床改善。
  • 滤泡辅助性T细胞和浆母细胞在临床应答者中选择性下降,无应答者中基本不变。
  • 上述细胞变化在独立队列和外部数据集中得到验证,提示其作为早期应答生物标志物的潜力。

核心结论

  • 甲氨蝶呤启动后出现快速且协调的免疫重构,滤泡辅助性T细胞和浆母细胞的早期变化可作为治疗应答的生物标志物。

研究设计与样本

  • 前瞻性纵向研究,对6例新诊断并启动甲氨蝶呤治疗的类风湿关节炎患者进行高参数免疫表型分析和外周血单个核细胞单细胞RNA测序。
  • 关键发现在22例类风湿关节炎独立队列中按临床应答分层验证,并与外部转录组数据集整合。

主要发现

  • 甲氨蝶呤诱导的免疫重塑最早在治疗3周时可检测到,并早于临床改善。
  • 滤泡辅助性T细胞和浆母细胞在临床应答者中选择性下降,在无应答者中基本不变。
  • 体外浆母细胞分化实验将甲氨蝶呤治疗与浆母细胞发育受损相关联。
  • 转录组网络分析识别出与甲氨蝶呤暴露相关的新调控枢纽,包括LMNA、SCO2、GVQW3和GIMAP家族成员。

临床怎么用

  • 滤泡辅助性T细胞和浆母细胞的早期变化有望作为甲氨蝶呤治疗类风湿关节炎应答的早期生物标志物。
  • 甲氨蝶呤的免疫效应在治疗3周内即可出现,临床评估应答时需考虑这一快速免疫重塑时间窗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Methotrexate (MTX) is the first-line treatment for rheumatoid arthritis (RA), yet its immunological mechanisms remain incompletely understood. This study aimed to define the time-resolved cellular and molecular changes induced by MTX. METHODS: In a prospective longitudinal study, newly diagnosed patients with RA initiating MTX were systematically profiled over time. We applied an integrated single-cell multiomics approach combining high-parameter immunophenotyping and single-cell RNA sequencing of PBMCs (peripheral blood mononuclear cells) obtained from 6 patients at baseline and at sequential time points during therapy. Functional in vitro assays were conducted to evaluate direct effects of MTX. Key findings were validated in an independent cohort of 22 patients with RA, stratified by clinical response, and integrated with external transcriptomic datasets. RESULTS: MTX-induced rapid immune remodelling that was detectable as early as 3 weeks after treatment initiation and preceded clinical improvement. The earliest and most pronounced alterations occurred in T follicular helper (Tfh) cells and plasmablasts, which declined selectively in clinical responders but remained largely unchanged in nonresponders across independent cohorts and external datasets, underscoring their potential as early biomarkers of treatment response. Functional plasmablast differentiation assays further linked MTX treatment to impaired development. Transcriptomic network analyses identified novel regulatory hubs associated with MTX exposure, including LMNA, SCO2, GVQW3, and members of the GIMAP family. To promote data accessibility, we developed an interactive single-cell browser for community-driven exploration. CONCLUSIONS: Together, these findings reveal an unexpectedly rapid and coordinated immune reconfiguration after MTX initiation and position early alterations in Tfh cells and plasmablasts as biomarkers of treatment response.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Preglej T, Tosevska A, Brinkmann M, et al. Time-resolved immune dynamics in rheumatoid arthritis under methotrexate therapy. Ann Rheum Dis. 2026. PMID: 42270499. doi:10.1016/j.ard.2026.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。